Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 05 2022
Historique:
entrez: 9 5 2022
pubmed: 10 5 2022
medline: 12 5 2022
Statut: ppublish

Résumé

Autosomal recessive retinitis pigmentosa (arRP) can be caused by mutations in the phosphodiesterase 6A (PDE6A) gene. Here, we describe the natural course of disease progression with respect to central retinal function (i.e., visual acuity, contrast sensitivity, and color vision) and establish a detailed genotype--phenotype correlation. Forty-four patients (26 females; mean age ± SD, 43 ± 13 years) with a confirmed genetic diagnosis of PDE6A-associated arRP underwent comprehensive ophthalmological examinations including best-corrected visual acuity (BCVA) with Early Treatment Diabetic Retinopathy Study charts, contrast sensitivity (CS) with Pelli-Robson charts at distances of 3 m and 1 m, and color vision testing using Roth 28-Hue and Panel D-15 saturated color cups. The most frequently observed variants were c.998+1G>A/p.?, c.304C>A/p.R102S, and c.2053G>A/p.V685M. Central retinal function in patients homozygous for variant c.304C>A/p.R102S was better when compared to patients homozygous for variant c.998+1G>A/p.?, although the former were older at baseline. Central retinal function was similar in patients homozygous for variant c.304C>A/p.R102S and patients heterozygous for variants c.304C>A/p.R102S and c.2053G>A/p.V685M, although the latter were younger at baseline. Annual decline rates in central retinal function were small. We conclude that the severity of the different disease-causing PDE6A mutations in humans with respect to central visual function may be ranked as follows: c.2053G>A/p.V685M in homozygous state (most severe) > c.998+1G>A/p.? in homozygous state > c.304C>A/p.R102S and c.2053G>A/p.V685M in compound-heterozygous state > c.304C>A/p.R102S in homozygous state (mildest). The assessment of treatment efficacy in interventional trials will remain challenging due to small annual decline rates in central retinal function.

Identifiants

pubmed: 35533076
pii: 2778808
doi: 10.1167/iovs.63.5.9
pmc: PMC9106976
doi:

Substances chimiques

Eye Proteins 0
Cyclic Nucleotide Phosphodiesterases, Type 6 EC 3.1.4.35
PDE6A protein, human EC 3.1.4.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9

Références

Invest Ophthalmol Vis Sci. 2009 Feb;50(2):801-13
pubmed: 18775863
Hum Mutat. 2020 Jan;41(1):140-149
pubmed: 31456290
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):479-89
pubmed: 18234989
JAMA Ophthalmol. 2018 Aug 1;136(8):920-928
pubmed: 29902293
Ophthalmologica. 2021;244(5):418-450
pubmed: 33567434
Clin Genet. 2010 Nov;78(5):495-8
pubmed: 21039428
Surv Ophthalmol. 1988 Nov-Dec;33(3):137-77
pubmed: 3068820
Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):159-179
pubmed: 32511120
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10177-81
pubmed: 7479749
JAMA Ophthalmol. 2020 Dec 1;138(12):1241-1250
pubmed: 33057649
Adv Exp Med Biol. 2018;1085:125-130
pubmed: 30578498
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643
pubmed: 28837425
Mol Vis. 2015 Aug 18;21:871-82
pubmed: 26321862
Hum Mol Genet. 2015 Oct 1;24(19):5486-99
pubmed: 26188004
J Int Neuropsychol Soc. 2001 Nov;7(7):813-24
pubmed: 11771624
Vision Res. 1998 Nov;38(21):3467-71
pubmed: 9893866
Adv Exp Med Biol. 2019;1185:103-107
pubmed: 31884596
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Ophthalmology. 1996 Mar;103(3):398-405
pubmed: 8600415
Front Biosci. 2005 May 01;10:1191-204
pubmed: 15769618
Front Neurosci. 2017 Jun 20;11:342
pubmed: 28676737
Hum Mol Genet. 2009 Jan 1;18(1):178-92
pubmed: 18849587
Invest Ophthalmol Vis Sci. 1988 Jan;29(1):50-63
pubmed: 3257208
J Fr Ophtalmol. 1995;18(10):578-83
pubmed: 8568160
Doc Ophthalmol. 2021 Oct;143(2):171-184
pubmed: 33818677
Hum Gene Ther. 2017 Dec;28(12):1189-1201
pubmed: 29212382
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Am J Ophthalmol. 1985 Mar 15;99(3):240-51
pubmed: 3976802
JAMA Ophthalmol. 2019 Jun 1;137(6):669-679
pubmed: 30998820
Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1859-65
pubmed: 10393062
Acta Ophthalmol (Copenh). 1982 Dec;60(6):907-16
pubmed: 6984998
Sci Rep. 2020 Jul 28;10(1):12552
pubmed: 32724127
Int J Mol Sci. 2020 Nov 03;21(21):
pubmed: 33153227
Nat Genet. 1995 Dec;11(4):468-71
pubmed: 7493036
Hum Gene Ther. 2017 Dec;28(12):1180-1188
pubmed: 29212391
JAMA Ophthalmol. 2019 Jun 1;137(6):679-680
pubmed: 30998807
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4664-71
pubmed: 18566474
Biom J. 2007 Dec;49(6):863-75
pubmed: 17638292
Ophthalmology. 1999 Feb;106(2):258-68
pubmed: 9951474

Auteurs

Laura Kuehlewein (L)

University Eye Hospital, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Torsten Straßer (T)

University Eye Hospital, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Gunnar Blumenstock (G)

Department of Clinical Epidemiology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Katarina Stingl (K)

University Eye Hospital, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

M Dominik Fischer (MD)

Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Barbara Wilhelm (B)

STZ eyetrial at the Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Eberhart Zrenner (E)

Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Werner Reichardt Centre for Integrative Neuroscience, Eberhard Karls University of Tübingen, Tübingen, Germany.

Bernd Wissinger (B)

Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Susanne Kohl (S)

Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Nicole Weisschuh (N)

Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.

Ditta Zobor (D)

Institute for Ophthalmic Research, Centre for Ophthalmology, Eberhard Karls University of Tübingen, Tübingen, Germany.
Department of Ophthalmology, Semmelweis University, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH